Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments

Opiant Pharmaceuticals (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will record a total of approximately $11.7 million in royalty and milestone payments for the five-month transition period ended December 31, 2017, as a result of a change in year-end from July 31 to December 31.

As quoted in the press release:

“We are extremely pleased with the growing commercial success of NARCAN continues to achieve in the United States,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “Moreover, we believe that our strong balance sheet positions us well to execute on our clinical development strategy.  Opiant has a robust addiction-related pipeline with significant market potential that we intend to advance as rapidly as possible.  Importantly, we expect to achieve multiple key milestones in 2018, including top-line data from our Phase II clinical trial for OPNT001 for the treatment of bulimia nervosa.”

Click here to read the full press release.